Systematic review: treatment pattern and clinical effectiveness and safety of pharmaceutical therapies for Crohn’s disease in Europe

Filippo Lelli1
Solomon Nuhoho2
Xin Ying Lee3
Weiwei Xu4
1EMEA Hemar, Janssen, Milan, Italy; 2Health Economics, Market Access and Reimbursement, Johnson & Johnson Middle East FZ LLC, Dubai, United Arab Emirates; 3EMEA Hemar, Janssen, Birkerød, Denmark; 4Pharmerit International, Rotterdam, the Netherlands

Background: Although many clinical trials have been conducted in treatments of Crohn’s disease (CD), whether the trial results were representative of daily practice needs to be supported by studies conducted in real-world settings.

Aim: This study aims to identify how CD is treated and what are the clinical effectiveness and safety of the pharmaceutical therapies of CD in real-world settings.

Methods: A systematic literature review was conducted based on Medline®, Embase®, and Cochrane. All publications were assessed for title/abstract and full-text according to a predefined study protocol. Data were extracted and reported.

Results: A total of 1,998 publications were identified. Fifty studies including six publications reporting treatment pattern and 44 studies reporting clinical effectiveness and safety of pharmaceutical therapies in CD management in Europe were included. 5-Aminosalicylic acid and corticosteroids were reported to be used among 14%–74% of CD patients. Immunomodulators were used by 14%–25% and 29%–31% of CD patients as an initial and follow-up treatment, respectively. Biological therapies were used by 25%–33% of CD patients. A trend toward an increasing use of immunomodulators and biological therapies in Europe has been reported in recent years. Approximately 50% of patients achieved remission on immunomodulator or biologic treatment, although a relapse rate of up to 23% has been reported.

Conclusion: There is a trend of treatment shift to immunomodulators and biologics in CD management. Clinical effectiveness of immunomodulators and biologics has been demonstrated, though with a lack of sustainability of the effectiveness.

Keywords: inflammatory bowel disease, real world evidence, biologics, immunomodulators, dose-escalation

Introduction
Crohn’s disease (CD) is an inflammatory bowel disease (IBD). It causes inflammation of the lining of digestive tract, which can lead to abdominal pain, severe diarrhea, fatigue, weight loss, and malnutrition. It is characterized by the formation of strictures, fistulas, ulcers, and granulomas in the mucosa. It may affect people in early childhood until late adulthood and has a significant impact on patient’s quality of life due to an increased prevalence of comorbidities.1 Although the gastrointestinal manifestation of CD can primarily affect the terminal ileum and colon, it can also compromise any region from the mouth to the rectum of the affected patients. The clinical manifestations of CD can include diarrhea or bloody diarrhea, malnutrition, abdominal pain, and weight loss. Extraintestinal findings, for instance, arthropathy or skin disorders, can also occur and have a substantial impact on the patient’s quality of life.2
A recent study from Tayside (in Scotland) indicates a prevalence rate of 157/100,000, meaning there are >115,000 people in the UK with CD at the present time. The causes of CD are widely debated. Smoking, genetic predisposition, and environmental factors are considered as important factors that are likely to play a role.

CD is a progressive disease with long-term damage to intestinal mucosa (if not controlled properly) and recurrent attacks, with acute exacerbations interspersed with periods of remission or less active disease. Treatment is largely directed at managing flares and inducing/maintaining remission, rather than curing, and active treatment of acute disease (inducing remission) should be distinguished from preventing relapse (maintaining remission).

Management options for CD include nutritional therapy, smoking cessation, drug therapy, and, in severe or chronic active disease, surgery. The aims of drug treatment are to reduce symptoms and maintain or improve quality of life, while minimizing toxicity related to drugs over both the short and long term. Glucocorticosteroids (ie budesonide) are recommended to be the first-line pharmaceutical for CD. 5-aminosalicylate (5-ASA) is recommended by the National Institute for Health and Care Excellence for CD patients in whom glucocorticosteroid treatment is contraindicated. For moderately active CD, azathioprine (AZA)/6-mercaptopurine (6-MP) or methotrexate in combination with steroids is a treatment option recommended by the European Crohn’s and Colitis Organisation (ECCO). Both National Institute for Health and Care Excellence and ECCO recommend biological therapies (eg, anti-tumor necrosis factor (TNF)-α inhibitors and integrin blocker) as an alternative for patients with objective evidence of active disease, who have previously been steroid-refractory, -dependent, or -intolerant. TNF-α inhibitors (eg infliximab) and/or immunomodulators are used as add-on treatments to glucocorticosteroids in case of severe and active CD when disease has not responded to conventional therapy or the glucocorticosteroid dose cannot be tapered. In recent years, there have been other drugs with other mechanisms of action under development, for example, humanized monoclonal antibody that targets interleukin-12 and interleukin-23, janus kinase inhibitors, and integrin inhibitors (eg, vedolizumab).

A number of clinical trials have been conducted to evaluate the pharmaceutical treatments in CD. Systematic literature reviews and meta-analyses of these clinical trials were conducted to understand the clinical effectiveness and safety of drugs used in treating CD. A meta-analysis including 12 clinical trials suggested that budesonide was no more effective than placebo for maintenance of remission; however, the overall quality of the evidence supporting this outcome was very low due to sparse data and high risk of bias (single-blind and no allocation concealment). Another meta-analysis including 27 studies showed that anti-TNF-α antibodies were superior to placebo in inducing remission of luminal CD. Anti-TNF-α antibodies were also superior to placebo in preventing relapse of luminal CD.

In a systematic literature review including 13 randomized clinical trials with a total of 1,211 participants, it was concluded that immunosuppressive drugs, such as AZA and 6-MP, are no more effective than placebo for inducing remission in CD.

To the best of our knowledge, there has been no published systematic literature review to investigate how these pharmaceutical therapies are adopted in real-world clinical practice and whether the results from the clinical trials can be generalized to real-world settings.

The objective of this work is to systematically review the treatment pattern of pharmaceutical inventions in CD in real-world clinical practice (in Europe) and the clinical effectiveness and safety of the pharmaceutical therapies that are labeled for the treatment of CD.

Methods

A systematic literature review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines on March 26, 2015, to identify relevant publications regarding current treatment pattern in practice, clinical effectiveness and safety of pharmaceutical therapies in real-life settings, patient preference in CD, and resource utilization/costs of treating CD. Among the aforementioned topics, current treatment pattern in practice and clinical effectiveness/safety of pharmaceutical therapies in real-life settings are the issues of interest for this study. A study protocol was developed to ensure the replicability of this literature review. The study protocol specified databases, limitations, and inclusion and exclusion criteria to be used in selection.

We searched Medline®, Embase®, and Cochrane (including Health Technology Assessment Database and National Health Service Economic Evaluation Database) to identify articles published from 2000 onwards. Furthermore, conferences including ECCO, conference of United European Gastroenterology, Groupe d’Étude Thérapeutique des Affections Inflammatoires du Tube Digestif, British Society of Gastroenterology, American Gastroenterological Association, and the Digestive disease week were also searched to identify relevant conference abstracts and proceedings in the past 3 years. In addition to the time limitation, the search was limited.
to humans, adult (≥18 years), English language, and “article, conference paper, conference proceedings, and review” as document type.

Search terms combined the disease of interest, that is, CD, study type (including all real-world evidence study types suggested by the Scottish Intercollegiate Guidelines Network), and keywords regarding treatment patterns and clinical effectiveness and safety/tolerability. The search strings used are presented in Table 1.

After removing duplicates, titles and abstracts of all results from the databases and conferences were reviewed by one reviewer according to the prespecified inclusion and exclusion criteria (a second reviewer was consulted in case of doubt). Full-text papers were accessed for all publications that were qualified in the title/abstract selection phase according to the same inclusion and exclusion criteria. In order to be able to target recent publications and have a geographic focus of the European countries, a further time limitation from year 2010 and a geographic limitation of Europe, or major European Union countries including UK, Germany, France, Spain, Italy, Sweden, Norway, Denmark, Finland, Belgium, the Netherlands, Luxembourg, and Portugal were used during the full-text selection phase. Publications excluded in the full-text selection phase were reported with reasons in a PRISMA chart.

Data were extracted on current treatment pattern in CD management and clinical effectiveness and safety of pharmaceutical therapies of CD, reported by real-world studies, that is, not in clinical trial settings.

Results
In this systematic literature review, a total of 1,998 publications were identified by searching Medline, Embase, and Cochrane database. After removing duplicates and screening the titles and abstracts of these 1,998 articles, 755 articles were retrieved and reviewed for full text. Based on the full-text publications, 705 articles were excluded for reasons according to the study protocol, including ineligible population (n=125); not interventions of interest, for example, surgical intervention and off-label drugs (n=169); not real-world studies (n=17); and irrelevant outcomes (n=123). Furthermore, 166 articles were excluded as they are either published before 2010 or conducted in countries other than those of interest. As the original literature review included also topics of patient preference and resource utilization, studies of these topics (n=92) fell out of the scope of this paper. Thirteen studies were not available for this literature review. The PRISMA chart that describes search and selection procedure is shown in Figure 1.

Table 1 Search terms (Medline® and Embase® search via ProQuest)

<table>
<thead>
<tr>
<th>Search</th>
<th>Search terms</th>
</tr>
</thead>
<tbody>
<tr>
<td>Indication</td>
<td>EMB.EXACT(“Crohn disease”) OR MESH.EXACT(“Crohn Disease”)</td>
</tr>
<tr>
<td>Study type</td>
<td>(EMB.EXACT(“case control study”) OR EMB.EXACT(“family study”) OR EMB.EXACT(“longitudinal study”) OR EMB.EXACT(“prospective study”) OR EMB.EXACT(“retrospective study”) OR EMB.EXACT(“observational study”) OR EMB.EXACT(“cohort analysis”) OR (“medical record review”) OR (TLAB(epidemiologic) pre/1 study) OR TLAB(“case control”) OR TLAB(“cohort pre/1 stud*) OR TLAB(“cohort analy*”) OR TLAB(Follow Up pre/1 stud*) OR TLAB(observational pre/1 stud*) OR TLAB(longitudinal) OR TLAB(retrospective) OR TLAB(“cross sectional”) OR TLAB(“chart review”) OR TLAB(“medical record review”) OR (MESH.EXACT(“Case-Control Studies”) OR MESH.EXACT(“Cohort Studies”) OR MESH.EXACT(“Cross-Sectional Studies”) OR MESH.EXACT(“Observational Study”) OR MESH.EXACT(“Prospective Study”) OR MESH.EXACT(“Retrospective Studies”) OR MESH.EXACT(“Longitudinal Studies”))</td>
</tr>
<tr>
<td>Treatment patterns</td>
<td>TLAB(escalation) OR TLAB(off-label) OR TLAB(label) OR (treatment pattern) OR (Standard treatment) OR (Standard therapy) OR (Standard of care) OR MESH.EXACT(“Standard of Care”) OR MESH.EXACT.EXPLODE(“Standard of Care”) OR SoC</td>
</tr>
<tr>
<td>Comparative effectiveness</td>
<td>TLAB(Activity Index) OR TLAB(CDAI) OR TLAB(Mucosal Healing) OR TLAB(Biomarkers) OR TLAB(Fecal Calprotectin) OR TLAB(Deep Remission) OR TLAB(dose escalation) OR TLAB(remission) OR TLAB(C Reactive Protein) OR TLAB(CRP) OR (comparative effectiveness) OR (clinical effectiveness) OR (space) OR TLAB(efficacy) OR MESH.EXACT(“Comparative Effectiveness Research”) OR MESH.EXACT.EXPLODE(“Comparative effectiveness”) OR (drug efficacy)</td>
</tr>
<tr>
<td>Safety and tolerability</td>
<td>AE OR (adverse events) OR (safety) OR (tolerability) OR MESH.EXACT.EXPLODE(“adverse drug reaction”) OR MESH.EXACT.EXPLODE(“Drug-Related Side Effects and Adverse Reactions”) OR MESH.EXACT.EXPLODE(“Drug-Related Side Effects and Adverse Reactions”) OR MESH.EXACT(“adverse drug reaction”) OR MESH.EXACT(“Safety”) OR MESH.EXACT(“drug tolerability”) OR MESH.EXACT(“drug tolerability”)</td>
</tr>
</tbody>
</table>

Combined S7 S1 AND S2 AND (S3 OR S4 OR S5)
This yielded 50 articles that were eligible for having their findings extracted and reported. Of these 50 publications, six studies reported the treatment pattern in real-world settings; 44 studies reported clinical effectiveness and safety of pharmaceutical therapies of CD in real-world clinical practice.

**Treatment pattern in real-world settings**

Patients with CD can be treated with dietary and lifestyle management, pharmaceutical, surgical, and other additional (eg, nutritional) interventions. In this literature review, the scope was limited to the use of pharmaceutical interventions in real-world settings only.

Six articles of interest were included for data extraction.14–19 Among these six studies, there are two cross-sectional studies and four longitudinal studies (including two retrospective studies and two prospective studies). A summary of the study design, reported patient characteristics, and outcomes of each of the included publications is provided in Table 2.

Taken together, these six publications seem to paint a homogenous picture of treatment patterns in the European countries. The most commonly prescribed classes of therapy are 5-ASA, corticosteroids, and immunomodulators. Increasing immunomodulator prescription and decreasing surgery rates and prescription of 5-ASA and corticosteroids have been reported in both the UK and Denmark.14,17 Moreover, the use of biological compounds has markedly increased during the initial year of treatment in both Eastern and Western Europe in the past decade.18 The following section reports how each category of pharmaceutical therapies is utilized in the real-life setting.

**5-ASA**

The usage of 5-ASA is reported in three publications.15,17,18 The percentage of patients using 5-ASA lies between 14% and 46.6%.15,17,18 The higher end of this range (46.6%) was reported by Bokemeyer et al in Germany in 2006.18 Although without further specification of CD patient population regarding disease severity/activity, this finding is comparable to what was reported for the 1995–2002 cohort in a longitudinal study (1979–2011) conducted by Runge et al.17 In that cohort, the cumulative probability of 5-ASA use was reported to be 50.2% and 55.3% of CD patients upon 5 and 15 years since diagnosis, respectively.17 It should be noted that these probabilities are more than halved in the subsequent 2003–2011 cohort, showing a substantial decrease in the use of 5-ASA among CD patients in recent years.17
<table>
<thead>
<tr>
<th>Study</th>
<th>Country</th>
<th>Study year</th>
<th>Treatment pattern</th>
<th>5-ASA</th>
<th>Biological therapy</th>
<th>Immunomodulators</th>
<th>Other therapies</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Corticosteroid</td>
<td>% (drug)</td>
<td>% (drug)</td>
<td>% (drug)</td>
<td>% (drug)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Budesonide</td>
<td>All patients: 22.9%</td>
<td>CDAI &lt;150: 14.6%</td>
<td>CDAI ≥150: 32.9%</td>
<td>All patients: 46.6%</td>
</tr>
<tr>
<td>Bokemeyer et al18</td>
<td>Germany</td>
<td>2006</td>
<td>Corticosteroids:</td>
<td>All patients: 22.9%</td>
<td>CDAI &lt;150: 45.0%</td>
<td>CDAI ≥150: 48.5%</td>
<td>All patients: 47.2%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Infliximab:</td>
<td>All patients: 8.2%</td>
<td>CDAI &lt;150: 6.1%</td>
<td>CDAI ≥150: 10.8%</td>
<td>All patients: 47.2%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Infliximab or adalimumab:</td>
<td>Initial: 6%</td>
<td>Follow-up: 18%</td>
<td>Various IMs:</td>
<td>Initial: 23%</td>
</tr>
<tr>
<td>Burisch et al13</td>
<td>Western Europe</td>
<td>2010</td>
<td>Initial: 35%</td>
<td>Initial: 19%</td>
<td>Follow-up: 14%</td>
<td>Infliximab or adalimumab:</td>
<td>Initial: 6%</td>
</tr>
<tr>
<td></td>
<td>Eastern Europe</td>
<td></td>
<td>Follow-up: 19%</td>
<td>Follow-up: 14%</td>
<td>Follow-up: 14%</td>
<td>Various IMs:</td>
<td>Initial: 23%</td>
</tr>
<tr>
<td>Magro et al19</td>
<td>Portugal</td>
<td>2005</td>
<td>N/A</td>
<td>N/A</td>
<td>Follow-up: 6%</td>
<td>Resection:</td>
<td>Initial: 31%</td>
</tr>
<tr>
<td></td>
<td>Spain</td>
<td></td>
<td>N/A</td>
<td>N/A</td>
<td>Follow-up: 6%</td>
<td>Resection:</td>
<td>Initial: 31%</td>
</tr>
<tr>
<td>Burisch16</td>
<td>Western Europe</td>
<td>2010</td>
<td>First 3 mo: 55%</td>
<td>Initial: 18%</td>
<td>Follow-up: 19%</td>
<td>Infliximab or adalimumab:</td>
<td>Initial: 6%</td>
</tr>
<tr>
<td></td>
<td>Eastern Europe</td>
<td></td>
<td>First 3 mo: 54%</td>
<td>Initial: 18%</td>
<td>Follow-up: 19%</td>
<td>Infliximab or adalimumab:</td>
<td>Initial: 6%</td>
</tr>
<tr>
<td>Ramadas et al14</td>
<td>UK</td>
<td>1986–2003</td>
<td>All CD patients:</td>
<td>First 3 mo: 63%</td>
<td>First 5 yr: 74%</td>
<td>Long term: 29%</td>
<td>First 3 mo: 7%</td>
</tr>
<tr>
<td></td>
<td>Group diagnosed 1986–1991:</td>
<td></td>
<td>Group diagnosed 1986–1991:</td>
<td>First 3 mo: 65%</td>
<td>First 5 yr: 75%</td>
<td>Long term: 44%</td>
<td>First 3 mo: 3%</td>
</tr>
</tbody>
</table>
|             | Group diagnosed 1998–2003: |            | Group diagnosed 1998–2003: | First 3 mo: 61% | First 5 yr: 76% | Long term: 19% | First 3 mo: 25% | First 5 yr: 45% | First 3 mo: 25% | First 5 yr: 45% | (Continued)
Table 2 (Continued)

<table>
<thead>
<tr>
<th>Study</th>
<th>Country</th>
<th>Study year</th>
<th>Treatment pattern</th>
<th>Corticosteroid</th>
<th>5-ASA</th>
<th>Biological therapy</th>
<th>Immunomodulators</th>
<th>Other therapies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rungeoe et al17,18</td>
<td>Denmark</td>
<td>1979–2011</td>
<td>Cohort III</td>
<td>Cohort III</td>
<td></td>
<td>TNF-α blockers:</td>
<td>Azathioprine:</td>
<td>First major surgery:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>First 1 yr: 26.5% T;</td>
<td>First 1 yr: 50.2%</td>
<td>49.9% O</td>
<td>First 5 yr: 54.4%</td>
<td>First 1 yr: 0.0%</td>
<td>Cohort II: 49.7%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>First 5 yr: 25.6% T;</td>
<td>First 9 yr: 55.3%</td>
<td>47.7% O</td>
<td>First 9 yr: 4.4%</td>
<td>First 5 yr: 26.5%</td>
<td>Cohort III: 31.4%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>First 9 yr: 28.8% T;</td>
<td></td>
<td>53.7% O</td>
<td></td>
<td>First 9 yr: 30.3%</td>
<td>Cohort IV: 17.5%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Cohort III</td>
<td>Cohort III</td>
<td></td>
<td>First 5 yr: 20.7%</td>
<td>Azathioprine:</td>
<td>First major surgery:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>First 1 yr: 11.1% T;</td>
<td>First 1 yr: 18.4%</td>
<td>24.0% O</td>
<td></td>
<td>First 1 yr: 8.2%</td>
<td>Cohort II: 49.7%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>First 5 yr: 22.1% T;</td>
<td>First 5 yr: 20.7%</td>
<td>39.8% O</td>
<td></td>
<td>First 5 yr: 14.1%</td>
<td>Cohort III: 31.4%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>First 9 yr: 14.7% T;</td>
<td>First 9 yr: 21.0%</td>
<td>41.1% O</td>
<td></td>
<td>First 9 yr: 15.1%</td>
<td>Cohort IV: 17.5%</td>
</tr>
</tbody>
</table>

Note: Percentages for Rungeoe et al are cumulative probability of using a treatment, which was calculated by the reviewer based on the absolute numbers of patients receiving the respective therapies and the total number of patients per cohort.

Abbreviations: 5-ASA, 5-aminosalicylic acid; CD, Crohn’s disease; CDAI, Crohn’s Disease Activity Index; IMs, immunomodulators; mo, month(s); N/A, not available; O, oral administration; T, topical administration; TNF-α, tumor necrosis factor-α; yr, year(s).

Corticosteroids

How corticosteroids are used to treat CD is reported in five publications.14–18 The percentage of CD patients treated with corticosteroids ranges between 14.6% (based on a study including CD patients in remission [Crohn’s Disease Activity Index [CDAI] <150]) and 74% (based on a study investigating the treatment of CD patients with a 5-year follow-up period).14 In the same study, Bokemeyer et al reported a higher proportion of corticosteroids use (32.9%) in patients with active disease (defined by CDAI >150 points).18 However, it is difficult to conclude that disease severity is the reason for the large variance of corticosteroid uptake reported across the studies based on the available evidence.

Some mixed findings are reported regarding the time point when corticosteroid is used since diagnosis. In a cohort study, Burisch et al found that the percentage of patients receiving corticosteroids is considerably lower in the long-term treatment of CD, as compared to the first months of initial treatment.13 However, in a population-based historical cohort study, Ramadas et al reported that the percentage of patients receiving corticosteroids peaks in the 5-year follow-up period (rather than in the first 3 months, ie, as initial treatment) for all historical cohorts, before the percentages decline in the long term.14

Two longitudinal cohort studies that investigated the change of prescription pattern of corticosteroid over time suggested a mixed picture.14,17 In a retrospective study covering the time period from 1979 to 2011, a steady and slight upward trend was identified regarding the percentage of patients treated with corticosteroids in recent years in Denmark.17 This finding is contradictory to the result reported by Ramadas et al, who reported a statistically lower corticosteroids use (within 5 years of diagnosis) in the cohort of 1998–2003 (19%), compared to the cohort of 1986–1991 (44%, P=0.001), based on a UK population-based study.14 The different results between the two studies may be partially explained by different study designs, for example, the shorter study time and cohort duration of Ramadas et al in comparison with Rungeoe et al (17 vs 32 years and 5 vs 7 years, respectively) and potential different treatment patterns in different countries.14,17

Besides the use of oral corticosteroid use, Rungeoe et al also juxtapose figures about the use of topical corticosteroid. The data clearly indicate that the percentage of oral corticosteroid treatment almost doubled that of topical treatment for any cohorts or follow-up periods. The usage of topical steroid has markedly declined from the 1995–2002 cohort (cumulative probability 31%) to the 2003–2011 cohort (cumulative probability 24%) (P<0.001).17
In most of the studies, the drug name of corticosteroid was not specified except a study by Bokemeyer et al. In that study, it was reported that budesonide was used among 22.9% of CD patients in Germany. This percentage was comparable to the percentage of CD patients with either active disease or disease remission (26.4% and 20.0%, respectively) in the study. However, the study provided no direct evidence that budesonide was used mainly by CD patients with active disease or in remission.

Immunomodulators
All six included publications reported the uptake of immunomodulators. The use of immunomodulator in treating CD varies across different treatment timing and different countries. In a prospective study with 12±3 months follow-up time, Burisch et al reported that in Europe, 1%–2% of CD patients used immunomodulators during the first 3 months after diagnosis. Approximately 14%–25% of CD patients had immunomodulators as an initial treatment (during the first year after diagnosis) and 29%–31% of CD patients had it as follow-up treatment. Some variance of the use of immunomodulators was noticed across countries. For example, the percentage of CD patients using this therapy was reported to be 63% and 47% in Spain and Portugal, respectively. In Denmark and the rest of Europe, immunomodulators were used among <31% CD patients.

Two longitudinal studies with long follow-up period: Ramadas et al (17 years follow-up) and Rungoe et al (16 years follow-up) suggested a trend of increasing use of immunomodulator among CD patients over the past 2 decades, both as an early therapy during the first year and overall therapy regardless of time to diagnosis. In the study conducted by Ramadas et al, three population-based cohorts (Group A: 1986–1991; Group B: 1992–1997; Group C: 1998–2003) of CD patients from Cardiff (UK) were investigated. It was found that between 1986 and 2003, there was a significant increase in the early and overall use of thiopurine (ie, AZA and 6-MP). Early use (within 1 year of diagnosis) of thiopurines increased from 3% in Group A to 12% in Group B and 25% in Group C (P<0.001). Five years after diagnosis, thiopurine had been used in 11% of Group A, 28% in Group B, and 45% in Group C (P<0.001). Similar trend was observed by Rungoe et al in Denmark, especially for the first year after diagnosis. Comparing the use of AZA between the 1995–2002 cohort and the 2003–2011 cohort, the cumulative probability of CD patients with AZA therapy were 15% versus 25% (P<0.001); 28% versus 36% (P=0.18); and 32% versus 39% (P=0.70) among these two cohorts for the first year, the first 5 years and the first 9 years after diagnosis, respectively.

Biological therapy
With the exception of Ramadas et al, all included publications provided data on the usage of biological compounds in CD treatment. The type of biological compounds under investigation varied between publications and was not always reported.

Among the publications, the highest percentage of CD patients with biological treatment was reported as 33% by Magro et al in a study among hospitalized CD patients in Galicia, Spain. The same study reported that 35% of the patients with their age at diagnosis between 17 and 40 years received biological therapy (being classified as severe refractory disease in the study). By comparison, all four other articles reported a much lower percentage of between 8% and 25% of CD patients receiving biological therapy.

From a longitudinal point of view, there seems to be an increase in the uptake of biological therapy. In a Danish retrospective study conducted by Rungoe et al, it was found that the highest percentage of biologic therapy use among CD patients was 15.1% in the 2003–2011 cohort, which was significantly higher compared with 4.4% which was reported in the 1995–2002 cohort.

Additional therapies
Of all included publications, only the study by Bokemeyer et al reports the use of additional, nonsurgical therapy (ie, rectal administration of 5-ASA, budesonide, or hydrocortisone) in Germany. It was reported that 4.1% of all CD patients received topical medication. This percentage was reported to be 3.2% and 5.2% for patients with inactive (CDAI score of <150) and active disease (CDAI ≥150), respectively.

Clinical effectiveness and safety of pharmaceutical treatments in real-world clinical practice
In total, 44 publications were included in this review regarding the clinical effectiveness and safety of pharmaceutical treatments of CD in real-world settings. Majority of the studies were longitudinal studies (n=43, 98%). A large part of the 43 longitudinal studies were retrospective studies (n=33); there are ten prospective studies. Twenty-five studies had a follow-up time of >12 months; five studies were short-term
ones with ≤12 months follow-up time; the rest of the studies failed to report their follow-up time.

Majority of the studies (n=23, 52.3%) were performed in an outpatient setting. Fourteen studies (31.8%) included both in- and outpatient data. For the remaining studies (15.9%), no information on treatment setting was specified.

It is important to note that there are substantial differences regarding how clinical effectiveness is measured (ie, how clinical remission/response is defined) across the observational studies. There are two general approaches adopted by the studies to define clinical remission/response. The first approach is to define clinical response according to symptoms control in a steroid-free setting, measured by either some standard tools (ie, CDAI [remission defined as CDAI <150], or Harvey–Bradshaw Index [HBI; remission defined as HBI <4]), judgment of a physician, or need for surgery. Another approach is to define clinical response with respect to the changes in some inflammatory indexes (also in a steroid-free setting), for example, erythrocyte sedimentation rate or C-reactive protein.

Therefore, although the results from these studies can be summarized, they cannot be compared with one another directly because of the variance among the measurements of the studies.

Infliximab

Clinical effectiveness

Dose escalation of infliximab was allowed from 5 mg/kg (according to the label) to 10 mg/kg in four studies.20–23 Taxonera et al24 reported a rate of dose intensification per patient-month of 1.4% for CD patients.24 The median time from baseline to intensification was 10.6 months.24 A similar rate of dose escalation was reported as 2.4% in 12 months and 5.0% in 24 months after infliximab treatment was initiated.25 When infliximab was reintroduced after a previous treatment (reasons of discontinuation unknown), 45% of patients received an intensified dosing schedule (>5mg/kg). In the rest of the studies, infliximab was used according to the label (5 mg/kg) or dosage was not reported. Clinical effectiveness of infliximab was reported using remission rate, response rate, recurrence rate, and need for surgery.

The percentage of patients reaching clinical remission at the end of the study was reported in four studies.20,21,23,25 A difference exists in the definition of clinical remission (eg, measured by HBI index or C-reactive protein values) and variance in patient groups in terms of age and disease activity. Remission rates at the end of the study were reported by three studies as 31% (median follow-up time ≥18 months),20 57% (median follow-up time 22 months),23 and 74% (follow-up time not reported).21 It is important to note that the two studies21,23 reporting relatively high remission rates included patients treated with an escalated infliximab dose of 10 mg/kg. One additional study conducted by Chauvin et al reported 1- and 2-year remission rates as 56% and 36%, respectively.25

In a retrospective hospital record analysis conducted by Antakia et al, 25% and 42% patients with complex CD (combined with fistula) achieved complete and partial response (defined by fistula drainage assessment endpoints), respectively, under infliximab therapy in UK.26 Also from a hospital record analysis but conducted in Portugal, Magro et al reported a sustained response (defined as response sustained for at least 1 year of treatment), short-term response (defined as response with <1 year of treatment), and response rate with therapeutic adjustment of 10.3%, 67%, and 22.7%, respectively.27

It was not uncommon that CD patients still experience recurrence under infliximab treatment. In a retrospective study with 12 years follow-up, Chauvin reported a recurrence rate of 68% among CD patients using infliximab treatment as maintenance therapy.28 A small-scale (N=12) prospective cohort study conducted by Sorrentino et al (median follow-up time: 3 years) found that infliximab did not show clinical benefit of preventing recurrence once patients stopped using it: among the 12 postsurgery CD patients using infliximab as maintenance therapy, ten (83%) reported recurrence after 3 years of infliximab treatment followed by 16 weeks of no treatment.29

As surgical interventions can be an option for severe CD patients, the need for surgery is also sometimes used as an indicator of the clinical effectiveness of a therapy. The rate of need for surgery varied a lot between the two studies that reported this outcome. In the retrospective study conducted in Portugal (median follow-up time 21 months), Magro et al reported a 1% surgery rate among patients receiving infliximab as maintenance therapy (N=148).37 In a Dutch database analysis, Brandse et al investigated the clinical effectiveness of a sequential therapy (starting with sequential infliximab and adalimumab, both for 3 months, and followed by infliximab treatment only after adalimumab discontinuation).20 It was reported that 24% of the patients underwent surgeries during the follow-up period (≥18 months).

Safety

A wide range of adverse events has been reported for infliximab, although the occurrence is rare for most of
them, including mortality,\textsuperscript{29} infusion reactions,\textsuperscript{20,23,25} rash,\textsuperscript{20} nausea,\textsuperscript{26} and herpes.\textsuperscript{23} Abscess is a more frequently reported adverse event among 31\% (N=48) of CD patients with infliximab treatment.\textsuperscript{29}

**Adalimumab**

**Clinical effectiveness**

In all studies where dosage was reported, the following regimen was used: 160 and 80 mg for induction at week 0 and 2, respectively, followed by maintenance treatment of 40 mg every 2 weeks. However, dose escalation of adalimumab was observed and reported by Bultman et al in over one-third of the cohort within a median follow-up time of 5 months.\textsuperscript{30} There are also a few studies that reported the impact of escalated dosage of adalimumab (ie, from 40 mg every 2 weeks to 80 mg every 2 weeks as maintenance dosage) on its clinical effectiveness.\textsuperscript{31–33} It was concluded that approximately one-third of the patients needed a dose escalation to maintain clinical response within 5–7 months.

As studies investigating the clinical effectiveness of infliximab in treating CD patients, clinical effectiveness of adalimumab was reported using measures such as remission rate, response rate, recurrence rate, and need for surgery. In all studies, CD remission is defined according to symptoms relief in a steroid-free environment, either assessed by global physician’s assessment or CDAI or HBI index.

With a definition of CDAI <150 or HBI <4 as remission for CD patients, Russo et al reported a remission rate of 57\% (N=61) among patients who were exposed to maintenance adalimumab therapy with an average follow-up of 8 months in the UK and Ireland.\textsuperscript{34} Similar rate was reported by Amiot et al, though with a very small sample size (N=5) and unclear definition of CD remission.\textsuperscript{29}

The reported 12 months remission rates varied widely (from 20\%\textsuperscript{35} to 86\%\textsuperscript{36}) across the three other studies that reported the rates.\textsuperscript{32,35,36} Average length of remission was reported by only one study, which found an average length of remission of 7.9 months (range 1–35 months).\textsuperscript{34}

In a retrospective study with 36 weeks follow-up period, Fortea-Ormaechea et al reported a complete response rate (defined as disappearance of symptoms according to the clinical evaluation of the supervising physician and normalization of all inflammation parameters without the need of glucocorticoids therapy) of 41.5\% and a partial response rate (defined as a significant improvement in symptoms and inflammation parameters, but without full resolution) of 35.8\% at the end of the follow-up.\textsuperscript{37} CD patients who do not respond to adalimumab seem to have the possibility of responding with higher dose of this drug. In a study investigating the outcome of dose escalation and de-escalation of adalimumab in treating CD patients, Baert et al concluded that adalimumab dose escalation reinduced clinical response for at least 6 months in 67\% of patients.\textsuperscript{31}

Similar to other treatments, adalimumab does not cure CD. The patients who achieved clinical remission/response are still at risk of recurrence. Chaparro et al reported a loss of response (LOR) in 18\% per patient-year of follow-up.\textsuperscript{36}

The need for surgery among CD patients under adalimumab treatment was investigated by Peters et al. In a retrospective analysis of the medical records of all CD patients in the Dutch province of North-Holland (median follow-up time =2 years), Peter et al reported that 9.3 abdominal surgical interventions had been performed per 100 patient-years by the end of follow-up.\textsuperscript{35}

**Safety**

A diverse picture was revealed regarding the safety of adalimumab in treating CD patients. In a study (36 weeks follow-up time) conducted by Fortea-Ormaechea et al (N=174), 18.4\% of the patients experienced adverse events.\textsuperscript{37} The most frequently reported adverse event was intra-abdominal abscess and rash: reported in five (15.6\%) and four (12.5\%) patients experienced adverse events, respectively. Other adverse events that were reported in less than three patients included injection pain, aggravated psoriasis, upper respiratory tract infections, anaphylactoid reaction, muscle pain, headache, varicella, pneumonia, dental infection, herpes zoster, diarrhea, and cough.\textsuperscript{37} Baert et al reported similar findings in a study with longer follow-up time (median follow-up: 14 months) and larger sample size (N=720).\textsuperscript{31} Severe adverse events that required hospitalization were reported to be rare (n<3) and included death; gastroenteritis; clostridium infection; acute viral syndrome with fever; herpes zoster/zona; pneumonia; exacerbation of CD such as flare-up, small bowel obstruction, perforation, abscess, actively drainage fistulae, elective surgery; pulmonary embolism; ulcerative skin lesions, renal cell carcinoma, multiple sclerosis, and stroke.\textsuperscript{31} Other rare adverse events included hair loss and malignancies.\textsuperscript{35}

**Thiopurines: AZA or 6-MP**

AZA was the treatment of interest in three studies.\textsuperscript{38–40} Five studies investigated thiopurines such as AZA or 6-MP as a treatment group, with results not distinguishable by drugs. Two studies investigated these drugs in combination with anti-TNF-\(\alpha\) drugs.\textsuperscript{41,42}
Clinical effectiveness

Relapse rate among thiopurine responders was reported by two studies. In a retrospective database analysis based on MICISTA database in France with a median follow-up time of 12.6 years, CD patients who responded to AZA (defined as achieving clinical remission during the fourth trimester after the introduction of AZA and off steroids) were followed-up for relapses. Cumulative relapse rates of 5 and 10 years after inclusion were reported to be 45% and 62%, respectively. In another retrospective study based on hospital records among CD patients who had continuous thiopurine use ≥35 months, Kennedy et al reported that 23% of patients had a moderate-to-severe relapse within 12 months of thiopurine withdrawal (N=129).43

For CD patients undergoing thiopurine therapy, the need for surgery was reported by a few papers with substantial difference in their results. Camus et al found that among responders to AZA, the need for surgery was 2.3% per patient-year. In another study conducted by Lee et al with a mixed CD population of AZA tolerance and intolerance groups (26% intolerance), the need for surgery was reported to be 48% of the whole sample.39

Safety

Mortality among patients undergoing AZA treatment was reported in several studies. In the study conducted by Camus et al with 12.6 years median follow-up time, eleven (5%) deaths were reported, including eight cancer-related deaths. Costantino reported one death among CD patients receiving either AZA or 6-MP (N=157), probably due to hemophagocytic lymphohistiocytic syndrome complicated by liver failure.44

Discussion

Immunomodulators and biological therapies have been developed as options for CD patients beyond 5-ASA and corticosteroids. There is evidence to support the early use of conventional immunomodulators and biological therapies in the treatment of moderate to severe CD, that is, for CD patients who do not respond to and/or tolerate 5-ASA or corticosteroids or for those who are otherwise steroid-dependent. Our findings regarding the treatment pattern confirmed a shift from traditional treatment using 5-ASA and corticosteroids to immunomodulators and biologics in the European countries.

This review identified the following unmet medical needs in managing CD patients.

- 5-ASA and corticosteroids remain the most widely used treatments for CD patients in the majority of the European countries, though whether clinical benefits outweigh side effects has been a topic of debate for decades. Immunomodulators and biologics, with better clinical effectiveness, are still second-line treatments for patients who either do not respond to or tolerate the first-line therapies according to the ECCO clinical guideline. However, we observed an increasing uptake of these drugs in recent years, which suggests that there is an unmet medical needs in the management of CD with the most widely used therapies (ie, 5-ASA and corticosteroids).

- Around half of CD patients responded to immunomodulators and biologics within 1 or 2 years after the treatment was initiated. However, this also means that the other half of patients did not achieve a satisfactory response to these therapies. Moreover, even among those who responded to the therapies, recurrence and relapse were not unusual. Surgeries were still required in some patients. For example, Chauvin et al reported a recurrence rate of 68% among CD patients with infliximab treatment in a 12-years retrospective study.

- With a mechanism of (targeted) modulating immune-mediated inflammation, immunomodulators and biologics do not cure the disease and have to be used as maintenance treatments. A substantial proportion of CD patients are likely to experience disease relapse/recurrence if they stop using these therapies. Even while using immunomodulators as a maintenance treatment, there was a high chance of LOR in the long term due to immunogenicity. Although there is no clear definition of LOR, some papers defined LOR in practical ways such as need for dose escalation over time, and sometimes also discontinuation of treatments. Dose escalation falls out of the scope of this literature review. However, dose escalation of adalimumab (ie, from 40 mg every 2 weeks to 80 mg every 2 weeks as maintenance dosage) was observed and reported by a few studies, which suggest a LOR with adalimumab. Indirect evidence of LOR with infliximab was also reported by Magro et al that the short-term response rate (67%) was much higher compared with a sustained response rate (10.3%) defined as response sustained for at least 1 year of treatment.
More options in the pharmaceutical management of CD are needed to meet the unmet needs of patients. This review is the first systematic literature review to summarize the treatment pattern of pharmaceutical therapies in CD management and the clinical effectiveness and safety of the major pharmaceutical therapies in the real-world setting. There are three potential limitations of this review.

First, this review has a geographic scope of European countries, including the UK, Germany, France, Spain, Italy, Sweden, Norway, Denmark, Finland, Belgium, the Netherlands, Luxemburg, and Portugal. There lies variance across the health care system in different countries, which leads to a potential accessibility issue of certain drugs (especially expensive drugs). Therefore, the findings, especially regarding treatment patterns, need to be interpreted with caution when they are to be generalized to other countries.

Second, a time limit of the past 5 years has been applied during the selection phase. Therefore, this review is not powered to draw a solid conclusion regarding a change of treatment pattern in CD management. The current conclusion regarding treatment trend was given on the basis of several longitudinal studies with long follow-up time.

Last, the studies included in this literature review have a mixed study design of cross-sectional study, retrospective study, and prospective study. This variance of the study design might have impact on the result and the direction of the impact is unclear. Therefore, the combined result of this review should only be taken as a qualitative summary of the finding.

Some knowledge gaps, which deserve further research, are revealed by this systematic literature review.

- Dose escalation of infliximab, adalimumab, and thiopurines has been observed and/or allowed in several studies, suggesting that it is an existing clinical practice to use higher-than-label dose in the management of CD patients. There is a lack of large-scale studies with long follow-up time to explore the impact of escalated dose of immunomodulators and biologics in terms of clinical effectiveness and safety in CD treatment.
- There is a lack of knowledge regarding the length of remission maintenance with immunomodulatory and biologics therapies. Although most of the studies identified by this review reported remission rates with a follow-up time of >18 months, there is no direct evidence showing how sustainable the clinical effectiveness of these therapies are.
- Limited evidence has been identified from this review to provide an overview of medications used for CD patients of different disease severities. This is an important area that deserves future investigation because the choice of medication in the treatment of CD highly depends on the severity of the disease.
- Both immunomodulators and biologics should be used as maintenance therapies to prevent recurrence of CD. However, most of the studies identified in this review are focused on the clinical effectiveness. Large-scale long-term safety studies in the real-world settings are needed for these therapies.
- There is a need for research studies to investigate the optimal mode of administration (systemic use vs local injection) in the treatment of perianal fistulae CD patients.

**Conclusion**

This systematic literature review aimed to give an overview of the treatment pattern of pharmaceutical therapies in CD management and clinical effectiveness and safety of the therapies in the real-world settings of the European countries. Although there are limited number of studies that investigated the use of pharmaceutical therapies in CD, these studies suggested a similar pattern in Europe. 5-ASA and corticosteroids have been widely used among CD patients, although there has been a trend of decreasing prescription in recent years. No studies investigating the clinical effectiveness and safety of 5-ASA and corticosteroids in the real-world setting has been identified, showing a lack of interest of researchers and/or physicians in this topic.

Immunomodulators and biological therapies appear to be promising treatment options in CD management and have been increasingly used in Europe in recent years, especially as long-term maintenance treatments. Due to the variance in how clinical effectiveness is measured across the studies, the results are not directly comparable. Nevertheless, clinical effectiveness is mainly measured by symptom-based measurements, for example, remission rate, response rate, CDAI, HBI. Based on the results reported by the identified studies, infliximab, adalimumab, and thiopurines are likely to achieve a remission rate of ~50% as maintenance therapies. Dose escalation was observed among approximately one-third and half of the CD patients receiving infliximab and adalimumab treatments, respectively, within 5–7 months. However, a substantial recurrence/relapse rate (18% per patient-year and cumulatively up to 83%) was also reported among patients who were under immunomodulator or biological treatments, and especially among those who discontinued the treatments.
Few major safety issues have been reported regarding these immunomodulators and biological therapies besides those that are widely recognized with these agents.

Acknowledgments
We would like to thank Bas van Dijk (employed by Pharmerit) for editing the manuscript. Search and selection and data extraction were supported by Krystallia Pantiri, Bas van Dijk, and Katharina Verleger, who are employees of Pharmerit International. This study received financial support from Janssen Pharmaceutical.

Disclosure
Weiwei Xu is employed by Pharmerit International. Filippo Lelli, Solomon Nuhoho, and Xin Ying Lee are employed by Janssen Pharmaceutical affiliates. The authors report no conflicts of interest in this work.

References


